Position in SLS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$444,512
New position
Shares Held
30,116
first reported quarter
Ownership
0.015%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#95
of 192 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in SLS
reported options exposure · as of Jun 30, 2026CallValue
$242,064
CallShares
16,400
PutValue
$3,377,088
PutShares
228,800
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names. SLS ranks #73 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
126,005 | $33,608,053 | |
| 2 | CYTK |
Cytokinetics Inc
|
239,728 | $20,422,428 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
288,233 | $16,492,692 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
386,183 | $14,393,040 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,596 | $14,089,509 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
334,854 | $11,180,775 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
347,898 | $11,111,862 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
353,226 | $10,487,279 |
All Filings in SLS
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $444,512 | 30,116 | Shares | Sole | 2026-08-03 | |
| 2026-06-30 | $242,064 | 16,400 | Call | Sole | 2026-08-03 | |
| 2026-06-30 | $3,377,088 | 228,800 | Put | Sole | 2026-08-03 | |
| No filing history on record for this holder in this stock. | ||||||